- Viasys Healthcare Inc.
- Delcath Systems Inc.
- Abbott Laboratories Inc.
- Abbott Spine
- Johnson & Johnson
- DePuy Synthes Spine Inc.
- Link Spine Group Inc.
- Apogent Technologies Inc.
- ID Biomedical Corp.
- Clinical Data Inc.
- Elan Corp. PLC
- Eurogentec SA
- Epoch Biosciences Inc.
- Genaissance Pharmaceuticals Inc.
- DNA Sciences Inc.
- Cephalon Inc.
- Celgene Corp.
- Martek Biosciences Corp.
- Exelixis Inc.
- PowderMed Ltd.
- CTI BioPharma Corp.
- Cell Therapeutics Europe SRL
- Biovail Corp.
- Johnson & Johnson
- Ortho Biotech Products LP
- Takeda Oncology
- Maxygen Inc.
- Amgen Inc.
- Tularik Inc.
- Viasys nets $63.2mm in FOPO
- Delcath Systems nets $2.17mm in follow-on
- Abbott buys Spinal Concepts for $170mm in cash
- DePuy AcroMed will buy Link Spine Group
- Apogent sells $250mm in notes offering
- ID Biomedical closes $25.5mm FOPO
- Novitron acquires Elan Dx, Landmark Scientific
- Eurogentec acquires Epoch Biosciences' oligonucleotide unit
- Genaissance to acquire DNA Sciences
- Cephalon sells $750mm in convertible debt offering
- Celgene raises $400mm in private placement of notes
- Martek Biosciences nets $72mm with FOPO
- Exelixis completes $74.7mm FOPO
- Chiron buys PowderJect for £542mm
- Cell Therapeutics acquires Novuspharma
- Biovail buys two of Wyeth's marketed drugs
- Millennium in giant cancer deal with Ortho Biotech
- Maxygen, Roche develop interferon alpha; terminated
- Tularik, Amgen discover and develop cancer therapeutics
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.